Clinical Trials

30 enrolled

Ovarian Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT04037254 2026-04-06

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

Prostatic Neoplasms

NCT06388733 2026-04-01

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Phase 3 Recruiting

450 enrolled

Brain Neoplasms, Glioblastoma

NCT03601923 2026-03-25

Niraparib in Patients With Pancreatic Cancer

Phase 2 Completed

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Phase 1 Recruiting

24 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06412120 2026-03-16

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

70 enrolled

Ovarian Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 1 Active not recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled

Phase EARLY_PHASE1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT05076513 2026-03-09

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

42 enrolled

Glioblastoma, Glioma

NCT04288687 2026-03-04

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Completed

11 enrolled 13 charts

Prostate Adenocarcinoma

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05442749 2026-02-17

PARPi-PANC

Phase 2 Terminated

2 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03830918 2026-02-12

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

59 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04068753 2026-02-10

STAR

Phase 2 Active not recruiting

66 enrolled

Phase EARLY_PHASE1 Active not recruiting

Uterine Cervical Neoplasms

NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

16 enrolled

Glioma

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

120 enrolled

Brain Neoplasms

NCT06086665 2026-02-04

REFIRM

Completed

850 enrolled